⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26921910 | 0.98 | ADRA2A (0.42) | — | |
| Hydrochloric Acid SCHEMBL4278980 | 0.98 | ADRA2A (0.42) | — | |
| SCHEMBL14234945 | 0.80 | NPSR1 (0.43) | — | |
| SCHEMBL22137313 | 0.80 | NPSR1 (0.43) | — | |
| SCHEMBL1746357 | 0.78 | — | — | |
| SCHEMBL30937277 | 0.78 | — | — | |
| SCHEMBL15426953 | 0.76 | — | — | |
| SCHEMBL31335160 | 0.76 | — | — | |
| SCHEMBL16127546 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL5077168 | 0.76 | NPSR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023237759-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR | ANAGENESIS BIOTECHNOLOGIES (FR) | 2023-12-14 | — | — | WO | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230278984-A1 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3750885-A1 | COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
| EP-3750885-A1 | COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-12-16 | — | — | EP | disclosed |
| CN-111683932-A | Compound with BET inhibition activity, preparation method and application thereof | 上海海和药物研究开发有限公司 | 2020-09-18 | — | — | CN | disclosed |
| WO-2019154329-A1 | COMPOUND HAVING BET INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREFOR | 上海海和药物研究开发有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-20040152725-A1 | Methods of treating cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | US | disclosed |
| EP-1408950-A2 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030232865-A1 | 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003072569-A1 | 1,4-DISUBSTITUTED BENZOFUSED CYCLOALKYL UREA COMPOUNDS USEFUL IN TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6525046-B1 | Inhibits inflammatory cytokines such as interleukin-1 and tumor necrosis factor; 1-(5-(2-hydroxy-1,1-dimethyl-ethyl) -2-p-tolyl-2H-pyrazol-3-yl)-3- (4-(2- morpholin-4-yl-ethoxy)-naphthalen-1-yl)-urea | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| WO-2003005999-A2 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| CN-1218472-A | Pharmaceutically useful compounds | ASTRA PHARMA PROD (GB) | 1999-06-02 | — | — | CN | disclosed |
| EP-0888347-A1 | PHARMACEUTICALLY USEFUL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034893-A1 | PHARMACEUTICALLY USEFUL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1997-09-25 | — | — | WO | disclosed |